Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas

Archives of Pathology and Laboratory Medicine

Volumn 121, Issue 6, 1997, Pages 578-584

  Tuck, Alan B ^a,b   O'Malley, Frances P ^a   Singhal, Hemant ^a   Tonkin, Katia S ^b   Harris, John F ^b   Bautista, Diosdado ^a   Chambers, Ann F ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; ONCOPROTEIN; OSTEOPONTIN; PROTEIN P53;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BILATERAL CANCER; BONE METASTASIS; BREAST CARCINOMA; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CASE REPORT; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; ONCOGENE C ERB; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; OSTEOPONTIN; PHOSPHOPROTEINS; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030926461     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Cattoretti G, Rilke F, Andreola S, et al. p53 expression in breast cancer. Int J Cancer. 1988;41:178-183.
2. Ostrowski JL, Sawan A, Henry L, et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. IPathol. 1991;164:75-81.
3. Davidoff AM, Humphrey PA, Iglehart JD, et al. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA. 1991;88:5006-5010.
4. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992;84:845-854.
5. Alfred DC, Clark CM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200-206.
6. Silvestrini R, Benini E, Daidone MG, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1993;85:965-970.
7. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S. Relationship between p53 expression and other prognostic factors in human breast carcinoma: an immunohistochemical study. Am J Clin Pathol. 1993;100:213-217.
8. MacGrogan G, Bonichon F, de Mascarel 1, et al. Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat. 1995;36:71-81.
9. O'Malley FP, Saad Z, Kerkvliet N, el ai. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erfa B2 in lymph node negative breast cancer. Hum Pathol. 1996;27:955-963.
10. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. N Engl J Med. 1989;244:707-712.
11. Thor AD, Schwartz LH, Koerner FC, et al. Analysis of c-erfa B-2 expression in breast carcinomas with clinical follow-up. Cancer Treat Res. 1989;49:7147-7152.
12. Raik S, Hazan R, Fisher ER, et al. Pathological findings from national surgical adjuvant breast project (Protocol D-06): prognostic significance of c-erbB-2 protein overexpression in primary breast cancer. I Clin Oncol. 1989;8:103-112.
13. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990;50:4332-4337.
14. Dati C, Muraca R, Tazartes O, et al. c-erfB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavourable clinical outcome. Int J Cancer. 1991;47:833-838.
15. Gullick WJ, Love SB, Wright C, et al. c-erbB-2 protein over-expression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 1991;63:434-438.
16. Lovekin C, Ellis 10, Locker A, et al. c-erfB-2 oncoprotein expression in primary and advanced breast cancer. Br I Cancer. 1991;63:439-443.
17. McCann A, Dervan PA, O'Regan M, et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Treat Res. 1991 ;51:3296-3303.
18. Winstanley J, Cooke T, Murray CD, et al. The long term prognostic significance of c-erfcB-2 in primary breast cancer. Br) Cancer. 1991;63:447-450.
19. Kamel OW, Franklin WA, Ringus JC, et al. Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol. 1989;134:107-113.
20. Isola JJ, Helin HJ, Helle MJ, et al. Evaluation of cell proliferation in breast carcinoma: comparison of Ki-67 immunohistocnemical study, DNA flow cytometric analysis, and mitotic count. Cancer. 1990;65:1180-1184.
21. Wintzer H-O, Zipfel 1, Schulte-Mönting J, et al. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer. 1991 ;67:421-428.
22. Weidner N, Moore DH II, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin" reactive MIB1 antibody. Hum Pathol. 1994;25: 337-342.
23. Vogelstein B. A deadly inheritance. Nature. 1990;348:681-682.
24. Butler WT. The nature and significance of osteopontin. Connect Tissue Res. 1989;23:123-136.
25. Denhardt DT, Butler WT, Chambers AF, et al. Osteopontin: role in cell signalling and adhesion. Ann N Y Acad Sciences. 1998;760:1-388.
26. Senger DR, Perruzzi CA, Rapadopoulos A. Elevated expression of secreted phosphoprotein I osteopontin (2ar) as a consequence of neoplastic transformation. Anticancer Res. 1989;9:1291-1299.
27. Craig AM, Nemir M, Mukherjee BB, Chambers AF, Denhardt DT. Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/ osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochem Biophys Res Commun. 1988;157:166-173.
28. Craig AM, Bowden GT, Chambers AF, et al. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer. 1990;46:133-137.
29. Chambers AF, Behrend El, Wilson SM, Denhardt DT. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Res. 1992;12:43-48.
30. Xuan JW, Hota C, Chambers AF, et al. Recombinant CST-human osteopontin fusion protein is functional in RCD-dependent cell adhesion. J Cell Biochem. 1994;54:247-255.
31. Bautista DS, Xuan JW, Hota C, et al. Inhibition of RGD-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. I Biol Chem. 1994;269:23280-23285.
32. Senger DR, Perruzzi CA, Cracey CR, et al. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res. 1988;48:5770-5774.
33. Singhal H, Bautista D, Tonkin K, O'Malley F, Chambers AF, Harris JF. Plasma levels of osteopontin in primary and metastatic breast cancer. Can J Surg. 1995;38(4, suppl):A14. Abstract 358.
34. Singhal H, Tonkin KS, Vandenberg TA, et al. Prospective evaluation of the prognostic significance of elevated plasma osteopontin in metastatic breast cancer. Proc Am Soc Clin Oncologists. 1996;15:504. Abstract 1614.
35. Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am I Pathol. 1994;145:610-623.
36. Hirota S, Ito A, Nagoshi J, et al. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers: possible involvement of osteopontin in development of calcifying foci. Lab Invest. 1995;72:64-69.
37. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol. 1995;146:95-100.
38. Bautista DS, Saad Z, Chambers AF, et al. Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem. 1996;29:231-239.
39. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.
40. Chambers AF, Wilson SM, Kerkvliet N, et al. Osteopontin in lung cancer. Lung Cancer. 1996;15:311-323.